Laparoscopic versus open gastrectomy for locally advanced gastric cancer after neoadjuvant chemotherapy: a comprehensive contrastive analysis with propensity score matching

Table 7 Multivariate analysis of risk factors for RFS and OS

Variables	RFS			OS
Variables	HR	95% CI	p-value	HR	95% CI	p-value
Tumor size^a (≥ 4 vs. < 4 cm)	1.448	0.788–2.659	0.233	2.230	1.131–4.400	0.021
Histological type (undifferentiated vs. differentiated)	1.026	0.537–1.958	0.939	1.051	0.516–2.140	0.890
Lymph-vascular invasion (yes vs. no)	1.328	0.737–2.392	0.346	1.414	0.751–2.663	0.283
Nerve invasion (yes vs. no)	0.989	0.497–1.971	0.976	0.956	0.459–1.993	0.905
Margin of resection (R1 vs. R0)	1.300	0.554–3.046	0.547	0.928	0.382–2.253	0.869
Clinical response of RECIST^b (PD or SD vs. PR or CR)	3.273	0.913–11.730	0.069	3.125	0.810–12.059	0.098
Tumor regression grade^c (2 or 3 vs. 1 or 0)	0.795	0.278–2.271	0.668	1.027	0.316–3.325	0.965
ypTNM stage^d (3 or 4 vs. PCR or 1 or 2)	2.386	0.805–7.068	0.117	2.509	0.787–8.000	0.120
Postoperative adjuvant chemotherapy (no vs. yes)	2.204	0.983–4.941	0.055	2.903	1.261–6.684	0.012

RFS relapse-free survival, OS overall survival, RECIST Response Evaluation Criteria in Solid Tumors, CR complete response, PR partial response, SD stable disease, PD progressed disease, PCR pathological complete response
^aReferred to the long diameter of tumor after neoadjuvant chemotherapy
^bAccording to the Response Evaluation Criteria in Solid Tumors (RECIST version 1.1)
^cAccording to the AJCC standard
^dAccording to the 8th edition of the American Joint Committee on Cancer Cancer Staging Manual

ISSN: 1477-7819